Search results
Results from the WOW.Com Content Network
Active immunotherapy is a type of immunotherapy that aims to stimulate the host's immune system or a specific immune response to a disease or pathogen and is most commonly used in cancer treatments. [ 1 ] [ 2 ] Active immunotherapy is also used for treatment of neurodegenerative disorders , such as Alzheimer's disease , Parkinson's disease ...
Biological response modifiers (BRMs) are substances that modify immune responses. They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs ), and they can either enhance an immune response or suppress it .
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
Biologic response modifiers act by altering the immune response of the human body. The mechanism of action is either through interfering with the effect of cytokines, inhibiting the costimulation of T cell activation, or inhibiting B cells. [15] Cytokines are proinflammatory and are responsible for regulating the human immune response. [17]
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.
[7] [8] Some publications point towards the effect of deoxycholic acid (DCA) as an immunostimulant [9] [10] [11] of the non-specific immune system, activating its main actors, the macrophages. According to these publications, a sufficient amount of DCA in the human body corresponds to a good immune reaction of the non-specific immune system.
However, strictly speaking, immunogenicity refers to the ability of an antigen to induce an adaptive immune response. Thus an antigen might bind specifically to a T or B cell receptor, but not induce an adaptive immune response. If the antigen does induce a response, it is an 'immunogenic antigen', which is referred to as an immunogen.
Therefore, immune cells can recognize the surface antigens on the tumor cells to elicit immune responses. Examples of drugs that exploit such a mechanism include pembrolizumab and telimomab . Apart from directing the inhibitory pathways, agonistic antibodies can target immunostimulatory receptors to elicit immune responses.